Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.95 billion
Profitability
Miscellaneous
Employees2,910
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) issued its earnings results on Monday, November, 4th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.53 by $0.07. The business earned $729 million during the quarter, compared to analysts' expectations of $709.01 million. Endo International had a negative return on equity of 99.08% and a negative net margin of 16.89%. The business's revenue for the quarter was down 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.71 EPS. View Endo International's Earnings History.
When is Endo International's next earnings date?
What guidance has Endo International issued on next quarter's earnings?
Endo International issued an update on its FY19 earnings guidance on Monday, November, 4th. The company provided earnings per share (EPS) guidance of $2.10-2.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.16. The company issued revenue guidance of $2.86-2.89 billion, compared to the consensus revenue estimate of $2.86 billion.
What price target have analysts set for ENDP?
13 brokers have issued 1-year price targets for Endo International's stock. Their forecasts range from $2.00 to $15.00. On average, they anticipate Endo International's share price to reach $7.42 in the next year. This suggests a possible upside of 53.2% from the stock's current price. View Analyst Price Targets for Endo International.
What is the consensus analysts' recommendation for Endo International?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.
Has Endo International been receiving favorable news coverage?
Media stories about ENDP stock have trended extremely negative on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Endo International earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Endo International.
Are investors shorting Endo International?
Endo International saw a decline in short interest in the month of October. As of October 15th, there was short interest totalling 38,100,000 shares, a decline of 6.4% from the September 15th total of 40,720,000 shares. Based on an average trading volume of 9,200,000 shares, the short-interest ratio is presently 4.1 days. Currently, 18.8% of the shares of the company are sold short. View Endo International's Current Options Chain.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Zogenix (ZGNX).
What other stocks do shareholders of Endo International own?
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)
Who are Endo International's major shareholders?
Endo International's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (0.54%), Rhumbline Advisers (0.24%), California State Teachers Retirement System (0.15%), Systematic Financial Management LP (0.08%), Russell Investments Group Ltd. (0.07%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Endo International stock include Nancy J Hutson, Roger H Kimmel and William P Montague. View Institutional Ownership Trends for Endo International.
Which major investors are selling Endo International stock?
ENDP stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Systematic Financial Management LP and Russell Investments Group Ltd.. Company insiders that have sold Endo International company stock in the last year include Roger H Kimmel and William P Montague. View Insider Buying and Selling for Endo International.
Which major investors are buying Endo International stock?
ENDP stock was bought by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., Rhumbline Advisers, Meeder Asset Management Inc., Nisa Investment Advisors LLC and California State Teachers Retirement System. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $4.84.
How big of a company is Endo International?
Endo International has a market capitalization of $1.10 billion and generates $2.95 billion in revenue each year. The company earns $-1,031,470,000.00 in net income (profit) each year or $2.89 on an earnings per share basis. Endo International employs 2,910 workers across the globe.View Additional Information About Endo International.
What is Endo International's official website?
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (NASDAQ ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
